# EDGAR Filing Document

**Accession Number:** 0001659617
**File Stem:** 0001437749-25-024411
**Filing Date:** 2025-8
**Character Count:** 6988
**Document Hash:** cc5ef5e864a72e5818f527e3256b9c05
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001437749-25-024411.hdr.sgml**: 20250801

**ACCESSION NUMBER**: 0001437749-25-024411

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 56

**CONFORMED PERIOD OF REPORT**: 20250801

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250801

**DATE AS OF CHANGE**: 20250801

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Moleculin Biotech, Inc.
- **CENTRAL INDEX KEY:** 0001659617
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 474671997
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37758
- **FILM NUMBER:** 251177083

**BUSINESS ADDRESS:**
- **STREET 1:** 5300 MEMORIAL DRIVE
- **STREET 2:** SUITE 950
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77007
- **BUSINESS PHONE:** 713-300-5160

**MAIL ADDRESS:**
- **STREET 1:** 5300 MEMORIAL DRIVE
- **STREET 2:** SUITE 950
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77007

?xml version='1.0' encoding='ASCII'? mbrx20250731_8k.htm

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934**

**DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): August 1, 2025**

![logobig.jpg](logobig.jpg)

**MOLECULIN BIOTECH, INC.**

(Exact Name of Registrant as Specified in its Charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-37758** | **47-4671997** |
| (State or Other Jurisdiction of<br> Incorporation or Organization) | (Commission File No.) | (I.R.S. Employer Identification No.) |

---

**5300 Memorial Drive, Suite 950, Houston, TX 77007**

(Address of principal executive offices and zip code)

**(713) 300-5160**

(Registrant's telephone number, including area code)

(Former name or former address, if changed from last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol (s)** | **Name of each exchange on which registered** |
| Common Stock, par value $.001 per share | MBRX | The NASDAQ Stock Market LLC |

---

------

---

| | |
|:---|:---|
| **Item 7.01**  | **Regulation FD Disclosure** |

---

On August 1, 2025, Moleculin Biotech, Inc. (the "Company") is using the attached presentation for its corporate presentation posted on the Company's website and is set forth as Exhibit 99.1 herein.

The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be "filed" for the purpose of the Securities Exchange Act of 1934, as amended ("Exchange Act"), nor shall it be incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended ("Securities Act"), unless specifically identified therein as being incorporated by reference.

---

| | |
|:---|:---|
| **Item 9.01**  | **Financial Statements and Exhibits.** |

---

(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |

---

---

| | |
|:---|:---|
| 99.1 | [<u>Investor Presentation dated July 2025</u>](ex_846275.htm) |

---

---

| | |
|:---|:---|
| 104 | Cover page Interactive Data File (formatted as Inline XBRL document) |

---

**<u>SIGNATURE</u>**

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| **MOLECULIN BIOTECH, INC.**  | **MOLECULIN BIOTECH, INC.**  |
| Date: | August 1, 2025 |
| By: | /s/ Jonathan P. Foster |
|  | Jonathan P. Foster |

---

## Exhibit 99.1

**Exhibit 99.1**

![slide_page01.jpg](slide_page01.jpg)

------

![slide_page02.jpg](slide_page02.jpg)

------

![slide_page03.jpg](slide_page03.jpg)

------

![slide_page04.jpg](slide_page04.jpg)

------

![slide_page05.jpg](slide_page05.jpg)

------

![slide_page06.jpg](slide_page06.jpg)

------

![slide_page07.jpg](slide_page07.jpg)

------

![slide_page08.jpg](slide_page08.jpg)

------

![slide_page09.jpg](slide_page09.jpg)

------

![slide_page10.jpg](slide_page10.jpg)

------

![slide_page11.jpg](slide_page11.jpg)

------

![slide_page12.jpg](slide_page12.jpg)

------

![slide_page13.jpg](slide_page13.jpg)

------

![slide_page14.jpg](slide_page14.jpg)

------

![slide_page15.jpg](slide_page15.jpg)

------

![slide_page16.jpg](slide_page16.jpg)

------

![slide_page17.jpg](slide_page17.jpg)

------

![slide_page18.jpg](slide_page18.jpg)

------

![slide_page19.jpg](slide_page19.jpg)

------

![slide_page20.jpg](slide_page20.jpg)

------

![slide_page21.jpg](slide_page21.jpg)

------

![slide_page22.jpg](slide_page22.jpg)

------

![slide_page23.jpg](slide_page23.jpg)

------

![slide_page24.jpg](slide_page24.jpg)

------

![slide_page25.jpg](slide_page25.jpg)

------

![slide_page26.jpg](slide_page26.jpg)

------

![slide_page27.jpg](slide_page27.jpg)

------

![slide_page28.jpg](slide_page28.jpg)

------

![slide_page29.jpg](slide_page29.jpg)

------

![slide_page30.jpg](slide_page30.jpg)

------

![slide_page31.jpg](slide_page31.jpg)

------

![slide_page32.jpg](slide_page32.jpg)

------

![slide_page33.jpg](slide_page33.jpg)

------

![slide_page34.jpg](slide_page34.jpg)

------

![slide_page35.jpg](slide_page35.jpg)

------

![slide_page36.jpg](slide_page36.jpg)

------

![slide_page37.jpg](slide_page37.jpg)

------

![slide_page38.jpg](slide_page38.jpg)

------

![slide_page39.jpg](slide_page39.jpg)

------

![slide_page40.jpg](slide_page40.jpg)

------

![slide_page41.jpg](slide_page41.jpg)